AbbVie Inc. (ABBV)

79.46
NYSE : Health Technology
Prev Close 79.50
Day Low/High 78.02 / 80.08
52 Wk Low/High 75.62 / 107.25
Avg Volume 5.71M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 117.53B
EPS 3.70
P/E Ratio 22.21
Div & Yield 4.28 (5.15%)
Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1]

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

NORTH CHICAGO, Ill., Nov.

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

- Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy[1,2]

I Don't Know Why, but There Is No Enthusiasm for This Market

The gloom is so thick you can cut it with a knife.

Nibble on This Bearish Strategy in Shake Shack: Market Recon

Nibble on This Bearish Strategy in Shake Shack: Market Recon

SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Clorox, Sirius XM Radio, New Relic, AbbVie, ShotSpotter and more.

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

Jim Cramer asks if the Fed is trying so hard to cool the economy that it could crush wage growth.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

Jim Cramer says that in good markets there are always multiple ways for investors to win.

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc.

The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against AbbVie Inc. (ABBV)

The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against AbbVie Inc. (ABBV)

Law Offices of Howard G. Smith reminds investors of the  October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc.

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/14/2018 settlement date, and AbbVie Inc is one of the most shorted stocks of the Russell 3000, based on 7.73 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc.

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc.

The New #66 Most Shorted S&P 500 Component: AbbVie

The New #66 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

10 Top Stocks With a History of Double-Digit Dividend Growth

10 Top Stocks With a History of Double-Digit Dividend Growth

Searching for dividends in this yield starved world? Check out these top 10 names.

TheStreet Quant Rating: B- (Buy)